Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25211250 | 1.00 | TRPM8 (0.41) | TRPM8CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL29858175 | 1.00 | TRPM8 (0.41) | TRPM8CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL1858360 | 1.00 | TRPM8 (0.41) | TRPM8CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL9963324 | 0.85 | CYP2D6 (0.40) | TRPM8CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL12468617 | 0.83 | CYP2D6 (0.38) | TRPM8CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL20738494 | 0.79 | CYP2D6 (0.38) | TRPM8CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL21547452 | 0.79 | CYP2D6 (0.41) | TRPM8CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL20738495 | 0.79 | CYP2D6 (0.38) | TRPM8CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL30824594 | 0.79 | CYP2D6 (0.38) | TRPM8CYP2D6CHRM1HRH1KCNH2 | |
| SCHEMBL6961060 | 0.79 | CYP2D6 (0.38) | TRPM8CYP2D6CHRM1HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| CN-116134035-B | 3- (1H-imidazol-2-yl) -2,3,8 a-tetrahydroindol-5 (1H) -one derivatives useful as factor XIA inhibitors | 詹森药业有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119431313-A | Antifungal compound, preparation method and application thereof | 上海交通大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| US-20230322791-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-10-12 | — | — | US | disclosed |
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-09-21 | — | — | US | disclosed |
| CN-102311387-A | 6-substituted 2,3,4, 5-tetrahydro-1H-benzo [d] aza as 5-HT2Creceptor agonists | LILLY CO ELI | 2012-01-11 | — | — | CN | disclosed |
| CN-101522693-B | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine deirvatives and their use in therapy | ASTRAZENECA AB | 2012-01-04 | — | — | CN | disclosed |
| CN-101516893-B | 5, 7-disubstituted [1,3] thiazolo [4,5-D ] pyrimidin-2 (3H) -one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2011-11-30 | — | — | CN | disclosed |
| US-8022062-B2 | 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| CN-101522693-A | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine deirvatives and their use in therapy | ASTRAZENECA AB (SE) | 2009-09-02 | — | — | CN | disclosed |
| CN-101516893-A | Novel 5, 7-disubstituted [1,3] thiazolo [4, 5-D ] pyrimidin-2 (3H) -one derivatives and their use in therapy | ASTRAZENECA AB (SE) | 2009-08-26 | — | — | CN | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | TRPM8 1364/4885CYP2D6 567/4885CHRM1 458/4885 |
| US-11932648-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | TRPM8 4428/4885CYP2D6 2839/4885CHRM1 4883/4885 |
| US-20230322791-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | TRPM8 4428/4885CYP2D6 2839/4885CHRM1 4883/4885 |
| US-20230295157-A1 | 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | SERPINC1, F11, TFPI2 | TRPM8 3319/4885CYP2D6 2325/4885CHRM1 4412/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | TRPM8 2069/4885CYP2D6 4249/4885CHRM1 1091/4885 |
| US-11970498-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | TRPM8 4428/4885CYP2D6 2839/4885CHRM1 4883/4885 |
| US-20240383902-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | TRPM8 4428/4885CYP2D6 2839/4885CHRM1 4883/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | TRPM8 4463/4885CYP2D6 1707/4885CHRM1 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.